Reduced expression of α<scp>G</scp>lc<scp>NA</scp>c in <scp>B</scp>arrett's oesophagus adjacent to <scp>B</scp>arrett's adenocarcinoma – a possible biomarker to predict the malignant potential of <scp>B</scp>arrett's oesophagus

Iwaya, Yugo; Hasebe, Osamu; Koide, Naoki; Kitahara, Kei; Suga, Tomoaki; Shinji, Akihiro; Muraki, Takamura; Yokosawa, Shuichi; Yamada, Shigenori; Arakura, Norikazu; Tanaka, Eiji; Nakayama, Jun

doi:10.1111/his.12296

Cited by 11 publications

(13 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous study of tumours from gastric cancer patients, we showed that loss of αGlcNAc expression in MUC6‐positive differentiated‐type adenocarcinoma was significantly correlated with invasion, stage, venous invasion of tumour cells, and poor prognosis of the patients . In addition, we revealed that decreased αGlcNAc expression in BO predicts the potential for development of BAC . These earlier findings combined with those of the present study suggest that αGlcNAc is an important biomarker, not only for predicting gastric cancer prognosis, but also for estimating the malignant potential of BO and PGA.…”

Section: Discussionsupporting

confidence: 84%

“…8 More recently, we revealed that reduced aGlcNAc expression relative to MUC6 expression was associated with malignant potential of gastric differentiatedtype adenocarcinoma. 9 We also showed that aGlcNAc expression levels relative to MUC6 expression levels were reduced in Barrett's oesophagus (BO) adjacent to Barrett's adenocarcinoma (BAC) as compared with BO without BAC, 10 indicating that aGlcNAc loss occurs not only in cancer cells but also in adjacent non-cancerous cells. However, the relationship between aGlcNAc loss and tumorigenesis in PGA remained unknown.…”

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Decreased expression of gastric gland mucin‐specific glycan α1,4‐linked N‐acetylglucosamine on its scaffold mucin 6 is associated with malignant potential of pyloric gland adenoma of the stomach

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Introductionmentioning

confidence: 95%

Decreased expression of gastric gland mucin‐specific glycan α1,4‐linked N‐acetylglucosamine on its scaffold mucin 6 is associated with malignant potential of pyloric gland adenoma of the stomach

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Hence, α1–4GlcNAc on core 2 prevents gastric cancer through its antibiotic properties toward H. pylori and by preventing protumorigenic inflammation in the stomach. In line with these mouse studies, loss of α1–4GlcNAc has been observed in patients with gastric carcinoma and Barrett’s adenocarcinoma and found to correlate with worse survival in gastric cancer (Iwaya et al, 2014; Shiratsu, Higuchi, & Nakayama, 2014). …”

Section: Altered O-glycan Structures Observed In Cancersupporting

confidence: 61%

Simple Sugars to Complex Disease—Mucin-Type O-Glycans in Cancer

Kudelka¹,

Ju²,

Heimburg-Molinaro³

et al. 2015

Advances in Cancer Research

202

192

View full text Add to dashboard Cite

Mucin-type O-glycans are a class of glycans initiated with N-acetylgalactosamine (GalNAc) α-linked primarily to Ser/Thr residues within glycoproteins and often extended or branched by sugars or saccharides. Most secretory and membrane-bound proteins receive this modification, which is important in regulating many biological processes. Alterations in mucin-type O-glycans have been described across tumor types and include expression of relatively small-sized, truncated O-glycans and altered terminal structures, both of which are associated with patient prognosis. New discoveries in the identity and expression of tumor-associated O-glycans are providing new avenues for tumor detection and treatment. This chapter describes mucin-type O-glycan biosynthesis, altered mucin-type O-glycans in primary tumors, including mechanisms for structural changes and contributions to the tumor phenotype, and clinical approaches to detect and target altered O-glycans for cancer treatment and management.

show abstract

“…may be driving the development of dysplasia/carcinoma from metaplastic condition. In line with this, studies have shown differential expression of glycan structures in tissue and serum samples during metaplasia-dysplasia-carcinoma sequence (23,(31)(32)(33)(34)(35)(61)(62)(63)(64)(65) The lack of glycosylation changes between healthy and BE was somewhat surprising because genomic studies suggest that BE and EAC share a common mutational profile that differs from healthy samples (59,60). The top candidate that differentiated between healthy and BE, NPL-APOB, was influenced by BMI.…”

Section: Discussionmentioning

confidence: 70%

Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma

Shah

Cao

Choi

et al. 2015

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

We report an integrated pipeline for efficient serum glycoprotein biomarker candidate discovery and qualification that may be used to facilitate cancer diagnosis and management. The discovery phase used semi-automated lectin magnetic bead array (LeMBA)-coupled tandem mass spectrometry with a dedicated data-housing and analysis pipeline; GlycoSelector (http://glycoselector.di. uq.edu.au). The qualification phase used lectin magnetic bead array-multiple reaction monitoring-mass spectrometry incorporating an interactive web-interface, Shiny mixOmics (http://mixomics-projects.di.uq.edu.au/Shiny), for univariate and multivariate statistical analysis. Relative quantitation was performed by referencing to a spiked-in glycoprotein, chicken ovalbumin. We applied this workflow to identify diagnostic biomarkers for esophageal adenocarcinoma (EAC), a life threatening malignancy with poor prognosis in the advanced setting. EAC develops from metaplastic condition Barrett's esophagus (BE). Currently diagnosis and monitoring of at-risk patients is through endoscopy and biopsy, which is expensive and requires hospital admission. Hence there is a clinical need for a noninvasive diagnostic biomarker of EAC. In total 89 patient samples from healthy controls, and patients with BE or EAC were screened in discovery and qualification stages. Of the 246 glycoforms measured in the qualification stage, 40 glycoforms (as measured by lectin affinity) qualified as candidate serum markers. The top candidate for distinguishing healthy from BE patients' group was Narcissus pseudonarcissus lectin (

show abstract

Reduced expression of αGlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma – a possible biomarker to predict the malignant potential of Barrett's oesophagus

Abstract: Reduced expression of αGlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma

Cited by 11 publications

References 51 publications

Decreased expression of gastric gland mucin‐specific glycan α1,4‐linked N‐acetylglucosamine on its scaffold mucin 6 is associated with malignant potential of pyloric gland adenoma of the stomach

Decreased expression of gastric gland mucin‐specific glycan α1,4‐linked N‐acetylglucosamine on its scaffold mucin 6 is associated with malignant potential of pyloric gland adenoma of the stomach

Simple Sugars to Complex Disease—Mucin-Type O-Glycans in Cancer

Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma

Contact Info

Product

Resources

About